Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/28/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Renier J. Brentjens

Wrong Dr. Renier J. Brentjens?


Phone: (212) ***-****  HQ Phone
Memorial Sloan-Kettering Cancer Center
1275 York Avenue Box # 460
New York , New York 10065
United States

Company Description: Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research and education in cancer....   more

Employment History

Board Memberships and Affiliations


  • MD
    SUNY Buffalo
  • PhD , microbiology
    SUNY Buffalo
81 Total References
Web References
Faculty | TAT Congress, 28 June 2015 [cached]
Renier J. Brentjens Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Pictured: Isabelle Rivière, Michel Sadelain ..., 20 July 2014 [cached]
Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
(From left) Investigators Isabelle Rivière, Michel Sadelain, and Renier Brentjens are founders of Juno Therapeutics.
Dr. Sadelain and two other Memorial Sloan Kettering researchers - Renier Brentjens, Director of Cellular Therapeutics, and Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility - are playing a critical role in the formation of Juno and are founding scientists of the company. (All three researchers will continue in their roles at Memorial Sloan Kettering.)
Pictured: Renier J. Brentjens
Renier J. Brentjens - Researcher Profile
Renier J. Brentjens, MD, ..., 18 Mar 2015 [cached]
Renier J. Brentjens, MD, PhD, Director, Cellular Therapeutics, Associate Attending Physician, Dept of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center
Alexandria Summit: Oncology 2013, 18 Sept 2013 [cached]
Renier J. Brentjens, MD, PhD
Associate Member, Associate Attending Physician, Leukemia Service & Chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Renier J. Brentjens, MD, PhD, obtained an MD and PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service.
As a medical oncology fellow during his training at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr. Brentjens became the principal investigator (PI) of his own laboratory.
As a PI, Dr. Brentjens successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells, designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second-generation CAR modified T cell clinical trials. Additionally, work in Dr. Brentjens' lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors, including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen.
"The immune system has evolved to ..., 18 Sept 2007 [cached]
"The immune system has evolved to police the body for infections and diseased cells, but it has a difficult time recognizing malignant cells since they largely appear normal to the immune system," said lead study author, Renier J. Brentjens, M.D., Ph.D., medical oncologist in the Leukemia Service at MSKCC."The idea is that we can take a patient's own T cells, re-educate them by inserting a gene into them that will enable them to produce a receptor to recognize B cell cancers, and then return them to the patient where they should be able to attack and kill the tumor cells."
Because the technique uses a patient's own T cells, there is little risk of compatibility issues or rejection, as there might be with human stem cell transplant, Dr. Brentjens adds.Human stem cell transplant, following radiation or chemotherapy, is currently incorporated into the treatment of several B cell malignancies.
In order to get T cells to recognize B cells, Dr. Brentjens and his colleagues created a gene that encodes for a cell-surface protein - an artificial T cell receptor called a chimeric antigen receptor -- designed to specifically bind to CD19, a molecule found on the surface of B cells and B cell cancers.Antigen receptors are what allow T cells, in combination with other parts of the immune system, to recognize and attack infected or malignant cells.This chimeric gene, formed from active portions of several immune system-related genes, creates the chimeric antigen receptor protein called 19-28z, which does not require other co-stimulatory signals to fully activate T cells, according to Dr. Brentjens.
Dr. Brentjens and his colleagues used an engineered retrovirus to insert the chimeric antigen receptor gene into T cell DNA.
"The repeated boosts of new T cells during therapy to improve T cell persistence enhances the efficacy of these T cells in eradicating cancerous B cells," said Dr. Brentjens."This concept of T cell persistence being critical to treatment efficacy is one we are further investigating in current and upcoming clinical trials."
The results have given the researchers further evidence that the technique will work in humans.When transplanted back into a patient, these engineered T cells could then attack and kill tumor cells bearing the CD19 protein."CD19 is not found on the surface of bone marrow stem cells, so these modified T cells are reasonably safe since they should not attack other blood forming cells in the bone marrow following treatment," Dr. Brentjens said.
Based on the results of their findings, the MSKCC researchers are currently conducting a clinical trial using this method in patients with chemotherapy-resistant CLL.CLL is currently considered an incurable cancer, Dr.
Brentjens said, although the disease generally progresses slowly.
Other People with the name "Brentjens":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.